Related Experiment Video
Updated: Mar 26, 2026
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Pazopanib in the treatment of advanced renal cell carcinoma
David Cella1, Jennifer L Beaumont2
1Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 633 N. St. Clair, 19th Floor, Chicago, IL 60611, USA.
Abstract:
Pazopanib is an orally available multitargeted tyrosine kinase inhibitor (a class of targeted therapies) that inhibits tumor angiogenesis and cell proliferation. The safety and efficacy of pazopanib (noninferior to sunitinib for progression-free survival) in patients with advanced or metastatic renal cell carcinoma (mRCC) have been demonstrated in several clinical trials. However, in addition to therapeutic efficacy, treatment choices should also take into account health-related quality of life (HRQoL) aspects of cancer therapy. Here, we summarize the HRQoL findings related to pazopanib use, based on patient-reported outcome measures; pazopanib has been shown to be superior to sunitinib on several HRQoL domains (including patient preference). A further consideration for treatment choice is how well the findings from clinical trials correlate with evidence from general clinical practice. This review therefore includes descriptions of real-world experience of pazopanib use in the treatment of patients with mRCC, following its approval by medical regulatory authorities in a number of countries. Naturalistic observational studies demonstrate that the efficacy of pazopanib in patients with mRCC is consistent with clinical trial findings. Similarly, consistent results were observed for the safety profile of pazopanib between observational studies and clinical trials, with most treatment-associated adverse events being mild to moderate in severity, and manageable.
Insights
Pazopanib, a targeted therapy for advanced renal cell carcinoma, offers comparable efficacy to sunitinib while demonstrating superior health-related quality of life. Real-world data confirm pazopanib
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Pazopanib is an oral multitargeted tyrosine kinase inhibitor used for advanced or metastatic renal cell carcinoma (mRCC).
- Clinical trials established pazopanib's non-inferior efficacy to sunitinib for progression-free survival in mRCC.
- Health-related quality of life (HRQoL) is a critical factor in cancer treatment decisions.
Purpose of the Study:
- To review health-related quality of life (HRQoL) findings for pazopanib in mRCC patients.
- To assess the real-world effectiveness and safety of pazopanib in mRCC.
- To compare clinical trial data with real-world evidence for pazopanib in mRCC.
Main Methods:
- Summarized HRQoL data from patient-reported outcome measures in clinical trials.
- Reviewed naturalistic observational studies on pazopanib use in mRCC post-approval.
- Analyzed efficacy, safety, and HRQoL outcomes from both trial and real-world settings.
Main Results:
- Pazopanib demonstrated superiority over sunitinib in several HRQoL domains, including patient preference.
- Real-world observational studies confirmed pazopanib's efficacy in mRCC patients, consistent with clinical trial findings.
- The safety profile in real-world practice mirrored clinical trial data, with manageable adverse events.
Conclusions:
- Pazopanib is a valuable treatment option for mRCC, offering comparable efficacy to sunitinib with significant HRQoL benefits.
- Real-world evidence supports the use of pazopanib in mRCC, aligning with clinical trial outcomes.
- Pazopanib provides a manageable safety profile in the treatment of advanced or metastatic renal cell carcinoma.
More Related Videos
Related Concept Videos
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies